Investors - Press Releases
|View printer-friendly version|
TRHC Fills the Information Gap on COVID-19 Proposed Therapies with a New Digital Resource
“There are knowledge gaps surrounding the proposed treatments for COVID-19,” said TRHC Chairman and CEO
Currently there are more than 20 therapies and treatments being studied across the globe. Many are being fast-tracked for immediate use, due to the unique conditions of the novel coronavirus and COVID-19.
“Designed for clinical use, our COVID-19 Treatment and Therapy Digital Resource provides an in-depth review of each medication’s mode of action, dosing guidelines, clinical trial information, adverse drug events, metabolism and elimination, as well as the proposed level of evidence based on the mechanism of action,” states TRHC Chief Scientific Officer
This press release includes forward-looking statements that we believe to be reasonable as of today’s date. Such statements are identified by use of the words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “projects,” “should,” and similar expressions. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release. These forward-looking statements include, among other things, our goals and expectations regarding the combined company and the integration of PW into TRHC, the expected synergies from the combined company and the expected financial and operating performance of TRHC following the completion of the acquisition. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: the risk that we may not be able to achieve our expectations for the combined companies due to challenges in integration and inability to retain key employees; fluctuations in our financial results; the acceptance and use of our products and services by PACE organizations and pharmacies; the need to innovate and provide useful products and services; risks related to changing healthcare and other applicable regulations; our ability to maintain relationships with a specified drug wholesaler; increasing consolidation in the healthcare industry; managing our growth effectively; our ability to adequately protect our intellectual property; the requirements of being a public company; our ability to recognize the expected benefits from acquisitions on a timely basis or at all; and the other risk factors set forth from time to time in our filings with the
T: (856) 912-5714
T: (215) 870-0829
T: (312) 451-2157
Source: Tabula Rasa HealthCare, Inc.